Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지

한국인에서 Streptococcus pneumoniae 분리주의 폐구균 표면 단백 A

Pneumococcal Surface Protein A of Streptococcus pneumoniae Isolates from Koreans

  • 김경호 (이화여자대학교 의과대학 소아과학교실)
  • Kim, Kyung Hyo (Department of Pediatrics, College of Medicine, Ewha Womans University)
  • 투고 : 2005.08.01
  • 심사 : 2005.08.12
  • 발행 : 2005.11.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적 : 현재 연구 개발되고 있는 PspA에 근거한 폐구균 단백 백신은 기존의 백신과 달리 여러 종류의 혈청형에 대해 동시에 광범위한 방어 면역을 유도할 가능성이 있다. 동물 실험에서 PspA는 폐구균 보균과 호흡기 감염 뿐 아니라 패혈증에 대해서도 방어 면역을 형성함이 보고되었다. 본 연구는 한국 소아와 어른에게서 분리된 폐구균에서 PspA 백신에 포함된 PspA family인 family 1과 family 2의 분포를 알기 위해 시행되었다. 방 법 : 총 89주의 폐구균을 대상으로 항혈청을 이용하여 슬라이드 응집 방법으로 폐구균 피막의 혈청형을 분류하였다. 또한 PCR을 이용하여 family 1과 family 2의 시발체를 사용하여 분리된 폐구균의 PspA family를 정하였다. 결 과 : 총 89주의 폐구균 분리주에서 17 종류의 폐구균 혈청형이 분류되었다. PspA 종류는 79주(88.8%)에서 결정되었는데 20주(22.5%)가 family 1, 59주(66.3%)가 family 2이었다. 아홉주(10.1%)에서 family 1과 2에 모두 양성 반응을 보였으므로 family 1과 2 단백을 포함하는 PspA 백신의 가능한 방어 범위는 98.9%이었다. 각 PspA family들은 균이 분리된 사람의 나이, 분리된 곳, 혹은 페니실린에 대한 감수성 등과 의미 있는 관련성이 없었으나 피막 혈청형에 따라서는 의미 있는 차이를 보였다. 결 론 : 본 연구에서 분리된 폐구균 분리주의 98.9%가 PspA family 1과 2에 속하였으므로 이를 포함한 백신은 폐구균에 대해 혈청형과 관련 없이 좀 더 광범위한 효과를 보일 것으로 추정된다. 향후 좀더 다양하고 많은 폐구균 분리주를 대상으로 PspA family의 연구가 이루어진다면 PspA 백신의 개발과 적용에 많은 도움이 될 것으로 생각된다.

Purpose : Pneumococcal protein vaccine based on pneumococcal surface protein A (PspA) is in development with the potential to offer a broad range of protection against different strains. PspA elicits protection in mice against fatal sepsis as well as carriage and lung infection. This study was performed to investigate the frequency of PspA families among Streptococcus pneumoniae recovered from Korean children and adults. Methods : A total of 89 pneumococcal isolates was included in the study. They were capsule serotyped by the slide agglutination assay with commercial antisera. PspA families were determined with polymerase chain reaction using the pair of primers for family 1 and family 2. Results : Seventeen pneumococcal serotypes were found in a total of 89 isolates. PspA typing was able to ascertain 79 of the 89 isolates (88.8 percent). Among these, 20 (22.5 percent) isolates were family 1 PspA, 59 (66.3 percent) were family 2. Moreover, because 9 (10.1 percent) isolates were of positive reactions for both, families 1 and 2 primers, the potential coverage of PspA vaccine was 98.9 percent. PspA families were not associated with age group, source of isolates, or penicillin susceptibility. However, the relative distribution of family 1 isolates to family 2 isolates was significantly different over capsular serotypes. Conclusion : The finding that 98.9 percent of Korean isolates belonging to PspA families 1 and 2 support the hypothesis that a human PspA vaccine covering a few PspA families could be broadly effective. The monitoring of the PspA families derived from large population-based isolates will be necessary in the context of vaccine development.

키워드

참고문헌

  1. Fedson DS, Musher DM. Pneumococcal polysaccharide vaccine. In : Plotkin SA, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia : WB Saunders Co, 2004:529-88
  2. Jacobs MR. Streptococcus pneumoniae : epidemiology and patterns of resistance. Am J Med 2004;117(Suppl 3A):3S- 15S https://doi.org/10.1016/S0002-9343(04)00442-5
  3. Cowan MJ, Ammann AJ, Wara DW, Howie VM, Schultz L, Doyle N, et al. Pneumococcal polysaccharide immunization in infants and children. Pediatrics 1978;62:721-7
  4. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser permanent vaccine study center group. Pediatr Infect Dis J 2000;22:187-95
  5. Cockeran R, Anderson R, Feldman C. Pneumolysin as a vaccine and drug target in the prevention and treatment of invasive pneumococcal disease. Arch Immunol Ther Exp 2005;53:189-98
  6. Miyaji EN, Dias WO, Gamberini M, Gebara VC, Schenkman RP, Wild J, et al. PsaA (pneumococcal surface adhesin A) and PspA (pneumococcal surface protein A) DNA vaccines induce humoral and cellular immune responses against Streptococcus pneumoniae. Vaccine 2001;20:805-12 https://doi.org/10.1016/S0264-410X(01)00395-4
  7. McDaniel LS, Yother J, Vijayakumar M, McGarry L, Guild WR, Briles DE. Use of insertional inactivation to facilate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med 1987;165:381-94 https://doi.org/10.1084/jem.165.2.381
  8. McDaniel LS, Scott G, Kearney JF, Briles DE. Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J Exp Med 1984;160:386-97 https://doi.org/10.1084/jem.160.2.386
  9. McDaniel LS, Sheffield JS, Delucchi P, Briles DE. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular serotype. Infect Immun 1991;59:222-8
  10. Briles DE, Hollingshead SK, King JE, Swift A, Braun P, Ferguson LM, et al. Immunization of human volunteers with recombinant PspA elicits antibodies that passively protect mice. J Infect Dis 2000;182:1694-701
  11. Ren B, McCrory MA, Pass C, Bullard DC, Ballantyne CM, Xu Y, et al. The virulence function of Streptococcus pneumoniae surface protein A involves inhibition of complement activation and impairment of complement receptor- mediated protection. J Immunol 2004;173:7506-12 https://doi.org/10.4049/jimmunol.173.12.7506
  12. McDaniel LS, McDaniel DO, Hollingshead SK, Briles DE. Comparison of the PspA sequence from Streptococcus pneumoniae EF5668 to the previously identified PspA sequence from strain Rx1 and ability of PspA from EF5668 to elicit protection against pneumococci of different capsular types. Infect Immun 1998;66:4748-54
  13. Hollingshead SK, Becker R, Briles DE. Diversity of PspA : mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 2000;68:5889-900 https://doi.org/10.1128/IAI.68.10.5889-5900.2000
  14. Swiatlo E, Brooks-Walter A, Briles DE, McDaniel LS. Oligonucleotides identify conserved and variable regions of pspA and pspA-like sequences of Streptococcus pneumoniae. Gene 1997;188:279-84 https://doi.org/10.1016/S0378-1119(96)00823-2
  15. Di Fabio JL, de Quadros C. Considerations for combination vaccine development and use in the developing world. Clin Infect Dis 2001;33(Suppl 4):S340-5 https://doi.org/10.1086/322571
  16. Nabors GS, Braun PA, Herrmann DJ, Heise ML, Pyle DJ, Gravenstein S, et al. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 2000;18:1743-54 https://doi.org/10.1016/S0264-410X(99)00530-7
  17. Vela Coral MC, Fonseca N, Castaneda E, Di Fabio JL, Hollingshead SK, Briles DE. Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from Colombian children. Emerg Infect Dis 2001;7:832-6. https://doi.org/10.3201/eid0705.010510
  18. Wu H-Y, Nahm M, Guo Y, Russell M, Briles DE. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage and infection, and sepsis with Streptococcus pneumoniae. J Infect Dis 1997;175:839-46 https://doi.org/10.1086/513980
  19. Briles DE, Hollingshead SK, Nabors GS, Paton JC, Brooks- Walter A. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 2000;19(Suppl 1):S87-95 https://doi.org/10.1016/S0264-410X(00)00285-1
  20. Miyaji EN, Dias WO, Tanizaki MM, Leite LC. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines : contribution of both humoral and cellular immune responses. FEMS Immunol Med Microbiol 2003;37: 53-7 https://doi.org/10.1016/S0928-8244(03)00108-1